A Mass That Isn't Cancer, in a Patient Steroids Might Actually Harm
IgG4-related disease masquerading as pancreatic cancer is treated with glucocorticoids by default — but this patient's own poorly controlled diabetes turns the default first-line choice into a genuine judgment call rather than a formality.
Marguerite L., a 61-year-old retired librarian, was referred to hepatobiliary surgery after a CT scan, obtained to investigate painless jaundice, showed a mass in the head of the pancreas highly suspicious for malignancy. Rather than proceeding directly to resection, her surgeon obtained an endoscopic ultrasound-guided biopsy first — a decision that changed her entire course, since pathology returned dense lymphoplasmacytic infiltrate, storiform fibrosis, and elevated tissue IgG4-positive plasma cells, consistent with autoimmune pancreatitis as a manifestation of IgG4-related disease rather than adenocarcinoma. Serum IgG4 came back markedly elevated, and imaging of her orbits and retroperitoneum, obtained once the diagnosis was suspected, showed additional subclinical involvement she had not reported any symptoms from.
The relief of that diagnosis — a treatable fibroinflammatory disease rather than pancreatic cancer — runs directly into a genuine complication in how to treat it. Glucocorticoids are the established first-line induction therapy per the 2015 international consensus guidance, with a strong track record across IgG4-RD's various organ manifestations. The alternative is not speculative either: Carruthers et al.'s prospective open-label trial reported response in 97% of patients, the large majority of them treated with rituximab and no glucocorticoid whatsoever. Marguerite, though, has type 2 diabetes that has been poorly controlled for the past year — A1c 9.4%, on maximal oral therapy — despite real effort on her part, including a recent switch to a stricter diet her endocrinologist had recommended. Beyond the diabetes, her baseline health is otherwise good: normal renal function, no cardiovascular disease, and an active life that still has her walking to the library most afternoons even now, weeks into a diagnosis that has understandably frightened her. Glucocorticoids are well known to worsen glycemic control substantially, often requiring insulin initiation even in previously well-controlled patients, which makes her case meaningfully different from the typical patient the first-line guidance was written for: not a contraindication in the absolute sense, but a real, quantifiable cost that a patient with normal glucose tolerance would not carry to nearly the same degree, and one her own endocrinologist raised unprompted the moment the treatment plan was mentioned to her.
Multidisciplinary consult, biopsy confirmed, treatment choice pending
I'd start with glucocorticoids per the 2015 international consensus guidance — that's still the best-evidenced first-line induction therapy for IgG4-related disease, and this disease can cause real, irreversible fibrotic organ damage if we don't get it under control promptly. I don't want to substitute a less-established first-line choice purely because of a comorbidity we can actively manage.
I understand the evidence argument, but I want her diabetes taken seriously as more than a manageable side issue — an A1c of 9.4% on maximal oral therapy already reflects a real struggle for glycemic control, and glucocorticoids at the doses used for IgG4-RD induction routinely push patients like her into needing insulin, sometimes durably. Carruthers's prospective open-label trial of rituximab in IgG4-related disease reported responses in 97% of thirty patients — and twenty-six of those thirty were treated with rituximab alone, without glucocorticoids at all. That is the part that matters for her.
I'm not saying steroids are absolutely contraindicated — I'm saying the cost isn't the same for her as it would be for a patient with normal glucose tolerance, and that difference should actually change the decision, not just get acknowledged and set aside.
I don't think you're actually as far apart as this is sounding. The strength of the steroid evidence base is real, and so is the glycemic cost — both of those can be true at once, which points toward a sequencing answer rather than picking one drug to the total exclusion of the other.
I'd propose a short, closely glucose-monitored glucocorticoid course — with insulin support proactively arranged rather than reactively added — for initial induction, with an early, planned transition to rituximab as the steroid-sparing maintenance agent rather than waiting to see how badly her glucose control deteriorates first. That keeps the stronger initial evidence base working for her while genuinely limiting her cumulative steroid exposure, rather than asking either of you to simply defer to the other's position.
Agreed: a four-week glucocorticoid induction course with proactively initiated insulin support, and rituximab scheduled to begin at week three to allow an early steroid taper — the clinical pharmacologist's sequencing plan let the rheumatologist's evidence-based preference and the endocrinologist's glycemic concern both stand without either being overridden.
Her jaundice and pancreatic mass both showed early improvement on follow-up imaging at six weeks, and her glucose control, while still requiring insulin, stayed within a range her endocrinologist described as manageable rather than dangerous — consistent with the sequencing plan achieving what both original positions were actually trying to protect.